Allergy Immunotherapy Market Trends

Growth Drivers

Growing Research and Development Activities - Increasing investments and financial support in the study of these allergies and the development of effective treatments for them. The market is expanding as a result of this. Immune Therapeutics is creating the biologic immunotherapy experimental medication AR101 for people with a peanut allergy.
Growing Prevalence of Allergies – An individual's quality of life is negatively impacted by allergic diseases because they disrupt many physiological processes. The demand for an efficient treatment method like allergy immunotherapy is growing due to the rising prevalence of allergies among people around the world as a result of increased exposure to numerous allergens such as pollens, mists, moulds, and others. For instance, in the US, about 25.7% of adults will have seasonal allergies by 2023, and about 31.8% of adults will have an allergy. This element is fueling market expansion.
Increasing Demand for Advanced Procedures – Pharma companies are able to expand their treatment options due to the rising prevalence of allergies and the ensuing medical therapies. Players are improving the already effective SLIT medications, which have been shown to treat atopic dermatitis, respiratory allergies, and a few food allergies. According to recent surveys, SLIT is still preferred by consumers over SCIT despite its drawbacks because of its accessibility. Additionally, a 10% annual increase in the prevalence of food allergies has been documented, which has increased the demand for immunotherapy for food allergies.

Challenges

Side Effects of Subcutaneous Injections – Patients do experience some alleviation from the subcutaneous injections, but there are some negative effects as well. The couple's adverse effects are anticipated to be hampered by these negative effects. During the projection period, these adverse consequences are anticipated to hurt the market.
Limitations Associated with Applicability of Allergy Immunotherapy
Poor Efficacy and Specificity of Immunotherapy

Allergy Immunotherapy Market: Key Insights

Base Year	2024
Forecast Year	2024 - 2037
CAGR	9.2%
Base Year Market Size (2024)	USD 1.85 billion
Forecast Year Market Size (2037)	USD 5.81 billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of allergy immunotherapy is assessed at USD 1.99 billion.

The allergy immunotherapy market size was over USD 1.85 billion in 2024 and is likely to reach USD 5.81 billion by the end of 2037, witnessing around 9.2% CAGR during the forecast period i.e., between 2025-2037. Growing research and development activities and growing prevalence of allergies will boost the market growth.

Asia Pacific industry is anticipated to hold largest revenue share 36% by 2037, due to rising presence of major key players in the region.

The major players in the market are ALK, Stallergenes Greer, Mylan N.V., HAL Allergy B.V., LETIPharma, AstraZeneca, Takeda Pharmaceuticals Company Ltd, Chugai Pharmaceutical Co., Ltd, Eisai Co. Ltd, Astellas Pharma Inc. and others.

Allergy Immunotherapy Market Trends